Protective effects of angiotensin II Type I receptor blocker on cerebral circulation independent of blood pressure

被引:38
|
作者
Kumai, Yasuhiro [1 ]
Ooboshi, Hiroaki [1 ]
Ago, Tetsuro [1 ]
Ishikawa, Eiichi [1 ]
Takada, Junichi [1 ]
Kamouchi, Masahiro [1 ]
Kitazono, Takanari [1 ]
Ibayashi, Setsuro [1 ]
Iida, Mitsuo [1 ]
机构
[1] Kyushu Univ, Dept Med & Clin Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan
关键词
autoregulation; angiotensin II type I receptor; cerebral blood flow; free radicals; remodeling;
D O I
10.1016/j.expneurol.2007.11.028
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Angiotensin II type I receptor (AT1R) blocker (ARB) has been reported to modify hypertensive cerebrovascular changes; however, it is not clear whether its protective effects are independent of blood pressure. The aim of this study was to clarify the role of AT1R-mediated signals in cerebral circulation by the chronic treatment with telmisartan, an ARB, at a dose that did not lower the blood pressure. Male spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY) were treated for 4 weeks from 16 weeks of ages with telmisartan (SHR-L: 0.3 mg/kg/day, SHR-H: 3 ing/kg/day, WKY-H: 3 mg/kg/day) or vehicle (SHR-V, WKY-V). Superoxide measured by a chemiluminescent assay or dihydroethidium fluorescence and vascular morphology were examined for the thoracic aorta (Ao), common carotid (CCA), middle cerebral (MCA) and basilar arteries (BA). After 4 weeks of treatment, the blood pressure significantly declined in SHR-H but not in SHR-L in comparison to SHR-V. The lower limit of cerebral blood flow (CBF) autoregulation, evaluated by hemorrhagic hypotension, was significantly lower in SHR-L and SHR-H than SHR-V In both SHR and WKY, the superoxide levels in the arteries were significantly attenuated by both doses of ARB. ARB also reversed vascular hypertrophy in Ao, CCA and BA and the inward remodeling in MCA. These results suggest that chronic treatment with telmisartan may therefore improve CBF autoregulation with a restoration of the vascular structure and an attenuation of superoxide generation, even at a dose that does not lower the blood pressure. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:441 / 448
页数:8
相关论文
共 50 条
  • [1] BLOOD-PRESSURE EFFECTS OF THE ANGIOTENSIN-II RECEPTOR BLOCKER, LOSARTAN
    WEBER, MA
    BYYNY, RL
    PRATT, JH
    FAISON, EP
    SNAVELY, DB
    GOLDBERG, AI
    NELSON, EB
    ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (04) : 405 - 411
  • [2] Angiotensin II type I receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis
    Fukuda, Michio
    Yamanaka, Tamaki
    Mizuno, Masashi
    Motokawa, Masahiro
    Shirasawa, Yuichi
    Miyagi, Sota
    Nishio, Takae
    Yoshida, Atsuhiro
    Kimura, Genjiro
    JOURNAL OF HYPERTENSION, 2008, 26 (03) : 583 - 588
  • [3] Effects of angiotensin II type I receptor blocker losartan on orthodontic tooth movement
    Moura, Adriana Pedrosa
    Montalvany-Antonucci, Carina Cristina
    de Albuquerque Taddei, Silvana Rodrigues
    Queiroz-Junior, Celso Martins
    Biguetti, Claudia Cristina
    Garlet, Gustavo Pompermayer
    Ferreira, Anderson Jose
    Teixeira, Mauro Martins
    Silva, Tarcilia Aparecida
    Andrade, Ildeu, Jr.
    AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS, 2016, 149 (03) : 358 - 365
  • [4] Angiotensin II Type-I Receptor Blocker, Candesartan, Improves Brachial-Ankle Pulse Wave Velocity Independent of Its Blood Pressure Lowering Effects in Type 2 Diabetes Patients
    Ishii, Hideto
    Tsukada, Toyohiro
    Yoshida, Masayuki
    INTERNAL MEDICINE, 2008, 47 (23) : 2013 - 2018
  • [5] Blood pressure-independent inhibition of Marfan aortic root widening by the angiotensin II receptor blocker valsartan
    Tehrani, Arash Y.
    White, Zoe
    Milad, Nadia
    Esfandiarei, Mitra
    Seidman, Michael A.
    Bernatchez, Pascal
    PHYSIOLOGICAL REPORTS, 2021, 9 (10):
  • [6] Management of Home Blood Pressure by Amlodipine Combined With Angiotensin II Receptor Blocker in Type 2 Diabetes
    Miyauchi, Katsumi
    Yamazaki, Tsutomu
    Watada, Hirotaka
    Tanaka, Yasushi
    Kawamori, Ryuzo
    Imai, Yutaka
    Ikeda, Shunya
    Kitagawa, Akira
    Ono, Yasuhiro
    Murayama, Fumio
    Choi, Jong Bock
    Suwa, Satoru
    Hayashi, Dobun
    Kishimoto, Junji
    Daida, Hiroyuki
    CIRCULATION JOURNAL, 2012, 76 (09) : 2159 - 2166
  • [7] Effects of Angiotensin II Type 1 Receptor Blocker on Ambulatory Blood Pressure Profile in Hypertensive Patients with Overt Diabetic Nephropathy
    Tamura, Kouichi
    Wakui, Hiromichi
    Masuda, Shin-ichiro
    Kanaoka, Tomohiko
    Ohsawa, Masato
    Maeda, Akinobu
    Dejima, Toru
    Yanagi, Mai
    Shigenaga, Atsu-ichiro
    Azuma, Koichi
    Mitsuhashi, Hiroshi
    Yoshida, Shin-ichiro
    Okano, Yasuko
    Ishigami, Tomoaki
    Toya, Yoshiyuki
    Umemura, Satoshi
    HYPERTENSION, 2009, 54 (04) : E89 - E89
  • [8] Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy
    Shin-ichiro Masuda
    Kouichi Tamura
    Hiromichi Wakui
    Tomohiko Kanaoka
    Masato Ohsawa
    Akinobu Maeda
    Toru Dejima
    Mai Yanagi
    Koichi Azuma
    Satoshi Umemura
    Hypertension Research, 2009, 32 : 950 - 955
  • [9] Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy
    Masuda, Shin-ichiro
    Tamura, Kouichi
    Wakui, Hiromichi
    Kanaoka, Tomohiko
    Ohsawa, Masato
    Maeda, Akinobu
    Dejima, Toru
    Yanagi, Mai
    Azuma, Koichi
    Umemura, Satoshi
    HYPERTENSION RESEARCH, 2009, 32 (11) : 950 - 955
  • [10] Changes of inflammatory markers are independent of blood pressure- and lipid-lowering effects of angiotensin II receptor blocker and statin combination therapy
    Villevalde, S.
    Mirilashvili, T.
    Kotovskaya, Y.
    Kobalava, Z.
    JOURNAL OF HYPERTENSION, 2008, 26 : S526 - S526